ERBB3 and head and neck squamous cell carcinoma: However, taking the difference in cetuximab resistance status between cell lines into account, a significant decrease in ΔMFI under hypoxia was observed for HER3 in acquired cetuximab‐resistant and PBS‐treated control HNSCC cell lines (P ≤ 0.010) (Fig. 3B).